Clinical trials update from the American Heart Association meeting 2009: HEAAL, FAIR-HF, J-CHF, HeartMate II, PACE and a meta-analysis of dose-ranging studies of beta-blockers in heart failure

European Journal of Heart Failure

Volumn 12, Issue 2, 2010, Pages 197-201

  Cleland, John G F ^a   Coletta, Alison P ^a   Freemantle, Nick ^b   Ahmed, Daniyal ^a   Rubis, Pawel ^a   Clark, Andrew L ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Heart failure; Randomized controlled trials

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CAPTOPRIL; CARVEDILOL; FERINJECT; IRON; LOSARTAN; METOPROLOL; NEBIVOLOL; PLACEBO; UNCLASSIFIED DRUG;

BRADYCARDIA; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG MEGADOSE; FERRITIN BLOOD LEVEL; HEART ASSIST DEVICE; HEART DEATH; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE PACING; HEMOGLOBIN BLOOD LEVEL; HOSPITAL; HUMAN; IRON DEFICIENCY; IRON THERAPY; LEFT VENTRICULAR ASSIST DEVICE; LOW DRUG DOSE; META ANALYSIS; MORBIDITY; MORTALITY; PACEMAKER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW;

ADRENERGIC BETA-ANTAGONISTS; AGED; AMERICAN HEART ASSOCIATION; ANTIHYPERTENSIVE AGENTS; CARBAZOLES; CLINICAL TRIALS AS TOPIC; FEMALE; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; IRON COMPOUNDS; LOSARTAN; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; PROPANOLAMINES; UNITED STATES;

EID: 75149193880     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfp199     Document Type: Conference Paper

References (19)

1. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-1587.
2. Dickstein K, Kjekshus J, OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360:752-760.
3. Cleland JGF, Freemantle N, Kaye G, Nasir M, Velavan P, Lalukota K, Mudawi T, Shelton R, Clark AL, Coletta AP. Clinical trials update from the American Heart Association meeting: V-3 fatty acids and arrhythmia risk in patients with an implantable defibrillator, ACTIV in CHF, VALIANT, the Hanover autologous bone marrow transplantation study, SPORTIF V, ORBIT and PAD and DEFINITE. Eur J Heart Fail 2004;6:109-115.
4. Konstam MA, Poole Wilson PA, Dickstein K, Drexler H, Justice SJ, Komajda M, Malbecq W, Martinez FA, Neaton JD, Riegger GA, Guptha S. Design of the heart failure endpoint evaluation of A-II antagonist losartan (HEAAL) study in patients intolerant to ACE-inhibitor. Eur J Heart Fail 2008;10:899-906.
5. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA, for the HEAAL Investigators. Effects of high dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009;374:1840-1848.
6. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Ryden L, Thygesen K, Utretsky BF. Comparative effects of low and high doses of the angiotensin converting enzyme inhibitor lisinopril on morbidity and mortality in chronic heart failure. ATLAS study group. Circulation 1999;100: 2312-2318.
7. Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, van der Meer P. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 2008;52:818-827.
8. Anker SA, Comin-Colet J, Filipatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Mori C, von Eisenhart Rothe B, Pocock S, Poole Wilson PA, Ponikowski P, on behalf of the FAIR-HF committees investigators. Rationale and design of Ferinject assessment in patients with iron deficiency and chronic heart failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur J Heart Fail 2009;11:1084-1091.
9. Anker SA, Comin-Colet J, Filipatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwna BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole Wilson PA, Ponikowski P, for the FAIR-HF trial Investigators. Ferric carboxymaltose in patients with heart failure iron deficiency. N Eng J Med 2009; doi: 10.1056/NEJMoa0908355; in press.
10. Hori M, Sasayama S, Kitabatake A, Toyo-oka T, Handa S, Yokoyama M, Matsuzaki M, Takeshita A, Origasa H, Matsui K, Hosoda S, MUCHA Investigators. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the multicentre car-vedilol heart failure dose assessment (MUCHA) trial. Am Heart J 2004;147: 324-330.
11. Bristow M, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Orie J, Smucker ML, Marsall G, Kelly P, Deitchman D, Anderson JL, for the Bucin-dolol Investigators. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation 1994;89:1632-1642.
12. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N, for the MOCHA Investigators. Carvedilol produces dose related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-2816.
13. Rousseau MF, Chapelle F, Van Eyll C, Stoleru L, Hager D, Van Neuten L, Pouleur H. Medium term effects of beta-blockade on left ventricular mechanics: a double blind placebo controlled comparison of nebivolol and atenolol in patients with ischemic left ventricular dysfunction. J Card Fail 1996;2:15-23.
14. Uhlir O, Dvorak I, Gregor P, Malek I, Spinarova L, Vojacek J, Van Nueten L. Nebi-volol in the treatment of cardiac failure: a double blind controlled clinical trial. J Card Fail 1997;3:271-276.
15. Colucci Ws, Kolias TJ, Adams KF, Armstrong WF, Ghali JK, Gottleib SS, Greenberg B, Klibaner MI, Kukin ML, Sugg JE, on behalf of the REVERT study group. Metoprolol reverses left ventricular remodelling in patients with asymptomatic systolic dysfunction. The reversal of ventricular remodelling with Toprolol-XL (REVERT) trial. Circulation 2007;116:49-56.
16. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10: 933-989.
17. Rose EA, Gelijns Ac, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, Long JW, Ascheim DD, Tierney AR, Levitan RG, Watson JT, Meier P, Ronan NS, Shapiro PA, Lazar RM, Miller LW, Gupta L, Frazier OH, Desvigne-Nickens P, Oz MC, Poirier VL, for the REMATCH study group. Long term mechanical left ventricular assistance for end-stage heart failure. N Eng J Med 2001;345:1435-1443.
18. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, Sun B, Tatooles AJ, Delgado RM, Long JW, Wozniac TC, Ghumman W, Farrar DJ, Frazier OH, for the HeartMate II Investigators. N Eng J Med 2009; doi: 10.1056/ NEJMoa0909938.
19. Yu CM, Chan JYS, Zhang Q, Omar R, Yip GWK, Hussin A, Fang F, Lan KH, Chan HCK, Fung JWH. Biventricular pacing in patients with bradycardia and normal ejection fraction. N Eng J Med 2009; doi: 10.1056/NEJMoa0907555.